It should be noted that the clinically used PHD inhibitors for treatment of anemia in chronic kidney disease appear to be safe, as far as is known, despite the perceived pleiotropic nature of HIF target genes (though, e.g., excessive EPO upregulation is, of course, toxic). This evidence concerns the gene EPO and anemia (phenotype).